Breaking News Instant updates and real-time market news.

EGY

VAALCO Energy

$2.17

-0.12 (-5.24%)

, MYL

Mylan

$38.48

-0.36 (-0.93%)

18:42
06/04/18
06/04
18:42
06/04/18
18:42

On The Fly: After Hours Movers

HIGHER: VAALCO Energy (EGY), up 8.3% after the company regained NYSE compliance... Mylan (MYL), up 5.2% after the FDA approved Mylan's Fulphila... Twitter (TWTR), up 3.7% after it was named to join the S&P 500. DOWN AFTER EARNINGS: Ascena Retail (ASNA), down 10.9%... Tarena (TEDU), down 4.6%. ALSO LOWER: Deciphera (DCPH), down 6% after it filed to sell 3.75M shares of common stock... Amgen (AMGN), down 1.4% after a Neulasta biosimilar was approved by the FDA.

EGY

VAALCO Energy

$2.17

-0.12 (-5.24%)

MYL

Mylan

$38.48

-0.36 (-0.93%)

TWTR

Twitter

$37.92

1.28 (3.49%)

ASNA

Ascena Retail

$3.65

0.32 (9.61%)

TEDU

Tarena

$9.44

-0.23 (-2.38%)

DCPH

Deciphera

$38.35

12.47 (48.18%)

AMGN

Amgen

$185.48

1.79 (0.97%)

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 27

    Jul

  • 13

    Nov

  • 07

    Jun

EGY VAALCO Energy
$2.17

-0.12 (-5.24%)

MYL Mylan
$38.48

-0.36 (-0.93%)

05/18/18
BERN
05/18/18
NO CHANGE
Target $54
BERN
Outperform
Biocon 483 letter won't delay approval of Mylan's Neulasta, says Bernstein
Bernstein analyst Aaron Gal said that the 483 letter for Biocon's Bangalore facility contains seven observations, all related to cleaning procedures, and does not contain any argument of systemic or recurring problem, suggestions of any of the procedure deviations creating patient risk or problems requiring changes in the facility structure or equipment. In a research note to investors, Gal said the 483 is viewed as being on the "lighter side," and can be "reasonably" addressed through change in procedure, and does not believe it will delay the tentative approval of Biocon/Mylan's Neulasta. The analyst has an Outperform rating and $54 price target on Mylan.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/23/18
JPMS
05/23/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan risk/reward favorable into June catalysts, says JPMorgan
JPMorgan analyst Chris Schott sees a favorable setup and risk/reward for Mylan shares heading into June. His downside case, in which biosimilar Neulasta, generic Advair and generic Restasis do not get approved in 2018, supports earnings per share in the low $5 range and a stock that he struggles to see sustainably below the mid $30's. The analyst's upside case, which has some mix of Advair, Neulasta and Restasis approved, supports a share price "well above" $50. Looking beyond near-term catalysts, Schott believes Mylan is "very well-positioned" within the generics space. He keeps an Overweight rating on the shares with a $53 price target.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
TWTR Twitter
$37.92

1.28 (3.49%)

05/02/18
DBAB
05/02/18
NO CHANGE
Target $32
DBAB
Buy
Twitter price target raised to $32 from $22 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Twitter to $32 while keeping a Hold rating on the shares. The analyst feels "increasingly positive" on Twitter due to "strong" product and business momentum across user engagement and monetization. However, he remains on the sidelines given the stock's "premium valuation on relatively slower growth."
06/01/18
MKMP
06/01/18
NO CHANGE
Target $43
MKMP
Buy
World Cup may be more meaningful driver for Twitter vs. 2014, says MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Twitter to $43 from $40 and maintained a Buy rating, telling investors in a research note that the impact of the World Cup could be a more meaningful driver for Twitter than in 2014, as the service is much improved since then and video was nascent on Twitter in 2014 but is now the largest source of monetization. He thinks the potential for Twitter to become a mass-market service in the future "still exists," which could lead to a significant revaluation if it happens.
04/30/18
BARD
04/30/18
NO CHANGE
Target $33
BARD
Neutral
Twitter's new partnerships highlight 'growing relevance,' says Baird
Disney's (DIS) and Viacom's (VIAB) announced live content/streaming partnerships with Twitter (TWTR) highlight Twitter's "growing relevance as a distribution platform," Baird analyst Colin Sebastian tells investors in a research note. He believes the partnerships should provide tailwinds for Twitter's video advertising business. Video accounts for greater than 50% of Twitter ad revenue and is its fastest growing ad format, Sebastian points out. The analyst says Disney and Viacom represent two of the company's biggest partnership wins to-date. He keeps a Neutral rating on Twitter with a $30 price target. The stock closed the trading day up 4.5% to $30.31.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $14
JEFF
Hold
Snap price target lowered to $14 from $17 at Jefferies
Snap last night posted the lowest top line growth it has seen as a public company and user metrics "show more trouble ahead," Jefferies analyst Brent Thill tells investors in a post-earnings research note titled "Ongoing Growing Pains." The analyst continues to recommend Facebook (FB) in Social and is more positive on Twitter (TWTR) than Snap during the latter's redesign. He lowered his price target for Snap to $14 and keeps a Hold rating on the shares.
ASNA Ascena Retail
$3.65

0.32 (9.61%)

08/15/17
08/15/17
NO CHANGE

FBR lowers Specialty Retail price targets ahead of Q2 reports
FBR Capital analyst Susan Anderson expects Specialty Retail earnings in Q2 to be overall in-line with consensus estimates, with a lighter top line and gross margin given the need to promote to drive traffic. The analyst views American Eagle (AEO) and L Brands (LB) as winners in the quarter. She upgraded American Eagle this morning to Buy. Anderson also lowered her price target for Neutral-rated Abercrombie & Fitch (ANF) to $11 from $13, for Neutral-rated Ascena Retail (ASNA) to $3 from $5, for Neutral-rated Foot Locker (FL) to $58 from $66, for Neutral-rated Francesca's to $10 from $13, for Neutral-rated Gap (GPS) to $25 from $28 and for Neutral-rated Urban Outfitters (URBN) to $16 from $24.
TEDU Tarena
$9.44

-0.23 (-2.38%)

08/22/17
NOMU
08/22/17
DOWNGRADE
Target $19.5
NOMU
Neutral
Tarena downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Andrew Orchard downgraded Tarena to Neutral and lowered its price target to $19.50 from $20.50 following weak Q3 revenue and margin guidance. The analyst expects margin softness to persist due to slower revenue recognition, higher R&D, and sustained investments and said underlying demand for certain classes may be weak as well.
11/22/17
JEFF
11/22/17
DOWNGRADE
Target $14.75
JEFF
Hold
Tarena downgraded to Hold from Buy at Jefferies
Jefferies analyst Johnny Kin Man Wong downgraded Tarena International to Hold and cut his price target for the shares to $14.75 from $21.50. The company's "aggressive" learning center rollout will be a drag on margins and "should cause some short term pain," Wong tells investors in a research note. The analyst, however, is positive on Tarena expanding into the K12 business.
04/04/18
LYON
04/04/18
UPGRADE
LYON
Buy
Tarena upgraded to Buy from Outperform at CLSA
DCPH Deciphera
$38.35

12.47 (48.18%)

06/03/18
PIPR
06/03/18
NO CHANGE
Target $35
PIPR
Overweight
Piper Jaffray incrementally positive on Deciphera shares
Piper Jaffray analyst Christopher Raymond is ncrementally positive on Deciphera's (DCPH) shares after what he sees as meaningfully de-risking data for DCC-2618 in refractory GIST at ASCO over the weekend. The analyst sees two key takeaways from the data, namely that DCC-2618 continues to compare well to Blueprint Medicines' (BPMC) BLU-285 efficacy wise, while maintaining a more favorable safety profile, and as he thinks Deciphera's 2L registration trial is meaningfully de-risked, in that sunitinib consistently confers just a single digit ORR. Raymond reiterates an Overweight rating and $35 price target on Deciphera shares.
05/31/18
PIPR
05/31/18
NO CHANGE
Target $35
PIPR
Overweight
Deciphera shares can outperform biotech index, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says recent meetings with Deciphera Pharmaceuticals management confirmed his bullish thesis on the name. The shares can outperform the biotech index as key updates on lead drug DCC-2618 in refractory gastrointestinal stromal tumors continue to roll out, starting this weekend at ASCO, Raymond tells investors in a research note. Further, he believes value from the company's systemic mastocytosis opportunity could start to "work its way into the stock" as a key initial read-out nears toward the end of 2018. The analyst keeps an Overweight rating on Deciphera with a $35 price target.
02/15/18
RILY
02/15/18
INITIATION
Target $43
RILY
Buy
Deciphera initiated with a Buy at B. Riley FBR
B. Riley FBR initiated Deciphera with a Buy and $43 price target.
06/04/18
JPMS
06/04/18
NO CHANGE
Target $33
JPMS
Overweight
Deciphera price target raised to $33 from $30 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Deciphera to $33 citing the "better-than-expected" phase I update for DCC-2618 at ASCO. The upadted increased the analyst's probability of success in the pivotal 2L Gist trial set to start this year. She keeps an Overweight rating on the shares.
AMGN Amgen
$185.48

1.79 (0.97%)

05/18/18
JEFF
05/18/18
NO CHANGE
Target $200
JEFF
Buy
Amgen price for Aimovig lower than expected, says Jefferies
Jefferies analyst Michael Yee says the confirmed list price of $6,900 for Amgen's (AMGN) Aimovig is lower than Street expectations of $7,000-$10,000. The analyst thinks the net price could fall to around $5,000-$6,000 as Allergan's (AGN) Botox is around $6,000. Amgen's pricing strategy sends a good message and fits well into the current reimbursement environment, Yee tells investors in a research note. He keeps a Buy rating on the shares with a $200 price target.
05/18/18
CANT
05/18/18
NO CHANGE
Target $18
CANT
Neutral
Amgen approval in migraine positive for Teva, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen's (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
05/18/18
WELS
05/18/18
NO CHANGE
WELS
Amgen migraine drug price may be below expectations, says Wells Fargo
The FDA, as expected, approved Amgen (AMGN) and Novartis' (NVS) first-in-class anti-CGRP treatment Aimovig for the prevention of migraine, Wells Fargo analyst David Maris tells investors in a research note. The only part of the news which may be somewhat unexpected could be the pricing, which came in at $575 per month or $6,900 annually, the analyst adds. He thinks some investors may have been expecting the price in the $12,000 range. Maris thinks there may be a potential negative read-through on the pricing for Teva (TEVA) and to a lesser extent, Allergan (AGN).
05/17/18
PIPR
05/17/18
NO CHANGE
Target $190
PIPR
Overweight
Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".

TODAY'S FREE FLY STORIES

RVI

Retail Value

$35.60

-0.36 (-1.00%)

, DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Initiation
Retail Value, DDR Corp. initiated  »

Retail Value initiated…

RVI

Retail Value

$35.60

-0.36 (-1.00%)

DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Hot Stocks
Goldman Sachs reports Q2 annualized ROE 12.8% »

Annualized return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$2.64

-0.12 (-4.35%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Hot Stocks
22nd Century comments on FDA's ANPRM to lessen nicotine in cigarettes »

22nd Century responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

, MSFT

Microsoft

$104.91

-0.51 (-0.48%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

NFLX

Netflix

$400.24

4.32 (1.09%)

MSFT

Microsoft

$104.91

-0.51 (-0.48%)

SNAP

Snap

$13.07

-0.295 (-2.21%)

FOXA

21st Century Fox

$46.71

-0.84 (-1.77%)

MS

Morgan Stanley

$48.91

0.85 (1.77%)

TGT

Target

$77.20

-0.525 (-0.68%)

FSLR

First Solar

$53.99

-0.08 (-0.15%)

CZR

Caesars

$11.63

0.075 (0.65%)

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

HFC

HollyFrontier

$68.91

0.25 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

BCRX

BioCryst

$6.20

0.01 (0.16%)

07:34
07/17/18
07/17
07:34
07/17/18
07:34
Upgrade
BioCryst rating change  »

BioCryst upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:33
07/17/18
07/17
07:33
07/17/18
07:33
Earnings
Goldman Sachs reports Q2 EPS $5.98, consensus $4.66 »

Reports Q2 revenue $9.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

, LB

L Brands

$32.01

0.31 (0.98%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Columbus signs renewal agreement with Victoria's Secret »

Alliance Data Systems…

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

LB

L Brands

$32.01

0.31 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

PRIM

Primoris

$28.12

-0.51 (-1.78%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Primoris announces electrical distribution award valued over $75M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$41.10

1.38 (3.47%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Recommendations
Zscaler analyst commentary  »

Zscaler price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

, QEP

QEP Resources

$12.09

-0.67 (-5.25%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

QEP

QEP Resources

$12.09

-0.67 (-5.25%)

HUBG

Hub Group

$49.10

-1.85 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

RPM

RPM

$60.00

-0.54 (-0.89%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Downgrade
RPM rating change  »

RPM downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

OSUR

OraSure

$16.28

-1.04 (-6.00%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Recommendations
OraSure analyst commentary  »

OraSure weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

07:26
07/17/18
07/17
07:26
07/17/18
07:26
Recommendations
Netflix analyst commentary  »

Canaccord views Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

07:25
07/17/18
07/17
07:25
07/17/18
07:25
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

07:24
07/17/18
07/17
07:24
07/17/18
07:24
Initiation
TechnipFMC initiated  »

TechnipFMC assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

QTS

QTS Realty Trust

$40.90

-0.05 (-0.12%)

07:23
07/17/18
07/17
07:23
07/17/18
07:23
Initiation
QTS Realty Trust initiated  »

QTS Realty Trust resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$356.01

5.2 (1.48%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Hot Stocks
Boeing signs integrated services agreement with Blackshape »

Boeing announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Oppenheimer remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$11.31

-0.63 (-5.28%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Initiation
Internap initiated  »

Internap resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

, MA

MasterCard

$204.05

-1.86 (-0.90%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
Visa, MasterCard analyst commentary  »

Visa price target raised…

V

Visa

$138.45

-0.91 (-0.65%)

MA

MasterCard

$204.05

-1.86 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

FDC

First Data

$22.24

-0.06 (-0.27%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
First Data analyst commentary  »

First Data price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.